MedTrace Logo

A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung Cancer

NCT06530797 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2024-07-31

No results posted yet for this study

Summary

The purpose of this observational study is to evaluate the safety and efficacy of Adebrelimab Injection in extensive-stage small cell lung cancer (ES-SCLC) under real-world conditions. Specifically, the study aims to assess the treatment of Adebrelimab Injection across various subgroups of ES-SCLC patients. The goal is to provide information on treatment patterns and effectiveness in real-life settings, explore potential predictive or prognostic biomarkers, and preliminarily evaluate the pharmacoeconomic indicators of Adebrelimab Injection treatment for extensive-stage small cell lung cancer.

Conditions

  • Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Interventions

DRUG

First-line Adebrelimab regiment for advanced stage ES-SCLC

First-line Adebrelimab in any regiment for advanced stage ES-SCLC

DRUG

Second-line and beyond Adebrelimab regiment for advanced stage ES-SCLC

Second-line and beyond Adebrelimab in any regiment for advanced stage ES-SCLC

Sponsors & Collaborators

  • Shanghai Pulmonary Hospital, Shanghai, China

    lead OTHER

Principal Investigators

  • Shengxiang Ren, MD. · Shanghai Pulmonary Hospital, Shanghai, China

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2026-09-01
Completion
2026-09-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06530797 on ClinicalTrials.gov